Scolaris Content Display Scolaris Content Display

Huperzine A for vascular dementia

Esta versión no es la más reciente

ver la versión actual 15 abril 2009

Referencias

Additional references

Aggarwal 2007

Aggarwal NT, Decarli C. Vascular dementia: emerging trends. Seminars Neurology 2007;27(1):66‐77.

APA 1980

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd Edition. Washington, DC: APA, 1980.

APA 1987

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd Edition. Washington, DC: APA, 1987.

APA 1994

American Psychiatric Association. Diagnostic criteria from DSM‐4. Washington, DC: APA, 1994.

Craig 2004

Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004744.pub2]

Craig 2006

Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004746.pub2]

Demaerschalk 2007

Demaerschalk BM, Wingerchuk DM. Treatment of vascular dementia and vascular cognitive impairment. The Neurologist 2007;13:37‐41.

Erkinjuntti 2000

Erkinjuntti T, et al. Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission 2000;59:23‐30.

Erkinjuntti 2004

Erkinjuntti T, et al. Treatment of vascular dementia ‐ evidence from clinical trials with cholinesterase inhibitors. Journal of the Neurological Sciences 2004;226:63‐6.

Farlow 2006

Farlow MR. Use of antidementia agents in vascular dementia: beyond Alzheimer's disease. Mayo Clinic Proceedings 2006;81(10):1350‐8.

Grossman 2006

Grossman H, et al. Dementia: a brief review. The Mount Sinai Journal of Medicine 2006;73:985‐92.

Gustavo 2005

Gustavo C, Roman. Vascular dementia prevention: A risk factor analysis. Cerebrovascular Diseases 2005;20(Suppl 2):91‐100.

Hachinski 1975

Hachinski VC, et al. Cerebral blood flow in dementia. Archives of Neurology 1975;32:632‐7.

Han 2006

Han Yan, et al. Review on clinical application of Huperzine A in China. New Drugs Clin Rem 2006;25(9):682‐8.

ICD 1989

Anonymous. The International classification of diseases. 9th Edition. Washington, DC: US Department of Health and Human Services, 1989.

Karirajan 2007

Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta‐analysis of randomised controlled trials. Lancet Neurology 2007;6:782‐92.

Knopman 2002

Knopman DS, et al. Incidence of vascular dementia in Rochester, Minn, 1985‐1989. Archives of Neurology 2002;59:1605‐10.

Li 2001

Li HN, et al. Huperzine A improve the cognitive function for patients with vascular dementia: report of the 30 cases. Modern Rehabilitation 2001;5:59.

Little 2008

Little JJ, et al. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opinion on Investigational Drugs 2008;17:209‐15.

Malouf 2004

Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD004395.pub2]

McShane 2006

McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003154.pub5]

O'Brien 2003

O'Brien JT, et al. Vascular cognitive impairment. Lancet Neuroloy 2003;2:89‐98.

O'Brien 2006

O'Brien JT. Vascular cognitive impairment. The American Journal of Geriatric Psychiatry 2006;14:724‐33.

Roman 2004

Roman GC. Facts, myths, and controversies in vascular dementia. Journal of Neurological Sciences 2004;226(1‐2):49‐52.

Wang 2004

Wang RP, et al. Huperzine A impact on ability of life of patients with vascular dementia: 36 cases of six months follow‐up. Chinese Journal of Clinical Rehabilitation 2004;8:3892.

Wang 2006

Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica 2006;27(1):1‐26.

WHO 1992

World Health Organization. The 10th revision of the International Classification of Disease and relative health problems (ICD‐10). Geneva: World Health Organization, 1992.

Zhang 2006

Zhang HY, Yan H, Tang XC. Neuroprotective effects of huperzine A : new therapeutic targets for neurodegenerative disease. Trends in Pharmacological Sciences 2006;27(12):619‐25.

Zhong 2004

Zhong ZG, et al. Clinical observation of huperzine A in the treatment of patients with vascular dementia. Journal of Hainan Medical College 2004;10:251‐2.
Table 1. Ovid MEDLINE search strategy

1. "alzheimer disease"/

2. "creutzfeldt jakob syndrome"/

3. exp Dementia/

4. "dementia vascular"/

5. "kluver bucy syndrome"/

6. "lewy body disease"/

7. "pick disease of the brain"/

8. "huntington disease"/

9. "delirium"/

10. "wernicke encephalopathy"/

11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10

12. dement*.mp.

13. alzheimer*.mp.

14. (lewy* and bod*).mp. [mp=title, original title, abstract, name of substance word, subject heading word]

15. deliri*.mp. [mp=title, original title, abstract, name of substance word, subject heading word]

16. ((cognit* or memory* or mental*) and (declin* or impair* or los* or deteriorat*)).mp. [mp=title, original title, abstract, name of substance word, subject heading word]

17. (chronic and cerebrovascular).mp. [mp=title, original title, abstract, name of substance word, subject heading word]

18. ("organic brain syndrome" or "organic brain disease").mp. [mp=title, original title, abstract, name of substance word, subject heading word]

19. "supra nuclear palsy".mp.

20. ("normal pressure hydrocephalus" and shunt*).mp. [mp=title, original title, abstract, name of substance word, subject heading word]

21. "benign senescent forgetfulness".mp.

22. (cerebr* and deteriorat*).mp. [mp=title, original title, abstract, name of substance word, subject heading word]

23. (cerebr* and insufficien*).mp. [mp=title, original title, abstract, name of substance word, subject heading word]

24. (confusion* or confused).mp. [mp=title, original title, abstract, name of substance word, subject heading word]

25. (Pick* and disease).mp.

26. (creutzfeldt or JCD or CJD).mp.

27. Huntington*.mp.

28. Binswanger*.mp.

29. korsako*.mp.

30. "korsakoff syndrome"/

31. (Wernicke* and (syndrome or encephalopathy)).mp.

32. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31

33. 11 or 32

34. huperzin*.mp. [mp=title, original title, abstract, name of substance word, subject heading word]

35. ayapin.mp. [mp=title, original title, abstract, name of substance word, subject heading word]

36. scoparon*.mp. [mp=title, original title, abstract, name of substance word, subject heading word]

37. drugs, Chinese Herbal/

38. exp Medicine, Oriental Traditional/

39. Plants, Medicinal/

40. 34 or 35 or 36 or 37 or 38 or 39

41. randomized controlled trial.pt.

42. controlled clinical trial.pt.

43. randomized.ab.

44. placebo.ab.

45. drug therapy.fs.

46. randomly.ab.

47. trial.ab.

48. groups.ab.

49. 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48

50. humans.sh.

51. 49 and 50

52. 33 and 40

53. 51 and 52
Figuras y tablas -
Table 1. Ovid MEDLINE search strategy
Ir a la tabla del protocolo